Can-Fite’s Namodenoson to Enter NAFLD/NASH Phase 2 Clinical Trial
Can-Fite BioPharma has concluded preparations for its Phase 2 trial evaluating namodenoson (CF102) for the treatment of non-alcoholic fatty liver disease (NAFLD). The study will…
News
Singapore Researchers Develop Probe That Improves Liver Cancer MRI Imaging
Researchers at the National University of Singapore have developed a probe that provides doctors with clearer and more accurate magnetic resonance images of liver cancer.
Hepko-V5 Cancer Vaccine Boosts Survival Rates in Advanced Liver Cancer Patients, Mongolian Study Finds
Patients with advanced, inoperable hepatocellular carcinoma (HCC) may highly benefit from Immunitor‘s new oral immunotherapeutic vaccine, Hepko-V5 (hepcortespenlisimut-L), according to results of a Phase 2 trial.
New Study Is Examining How Doctors Manage Patients with Liver Disease
A large observational study is looking at how doctors manage people with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver disease (NAFL). TARGET PharmaSolutions is conducting the…
FDA Approves Stivarga as Treatment for Common Form of Liver Cancer
The U.S. Food and Drug Administration (FDA) approved the use of Stivarga (regorafinib) for the treatment of patients with hepatocellular carcinoma (HCC), a form of…
Radiation-delivering Microspheres Fight Liver Cancer as Well as Chemo, Clinical Trial Indicates
Radiation-delivering microspheres developed by Sirtex are as effective as Nexavar (sorafenib) chemotherapy against a liver cancer known as hepatocellular carcinoma (HCC), according to a Phase 3…
Exposure to High-Fat Diet in Womb and During Breastfeeding Linked to Liver Disease
A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…
Fecal Transplant Improves Cognitive Malfunction Caused by Liver Disease, Study Finds
Transplanting fecal bacteria from a healthy person to someone who has a liver-connected brain impairment may be an effective way to treat the condition, known…
Enanta’s EDP-305 Therapy Shows Promise in Treating Non-Alcoholic Fatty Liver Disease
Candidate drug EDP-305 reduced fibrosis progression and improved non-alcoholic fatty liver disease (NAFLD) and primary biliary cholangitis (PBC) disease settings in several preclinical animal models, says…
NeuroVive’s NV556 Inhibits Liver Tumor Growth in Mice, Study Indicates
NV556 inhibited tumor growth in mice with a liver disease known as non-alcoholic steatohepatitis, or NASH, according to a study by its maker, NeuroVive Pharmaceutical AB.
